EFFECT OF RISANKIZUMAB TREATMENT ON EXTRAINTESTINAL MANIFESTATIONS (EIMS) IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE (CD): RESULTS FROM THE ADVANCE, MOTIVATE AND FORTIFY STUDIES

Subrata Ghosh  ¹     Marc Ferrante  ²     Britta Siegmund  ³     Takehiro Arai  ⁴     Walter Reinisch  ⁵     Naomi Martin  ⁶     Joanne Rizzo  ⁶     Kristina Kligys  ⁶     Yafei Zhang  ⁶     Javier Zambrano  ⁶     Jasmina Kalabic  ⁷     David P. Hudesman  ⁸     Edouard Louis  ^9    
1 University College Cork, Birmingham, Ireland
² University Hospitals Leuven, Leuven, Belgium
³ Charité - Universitätsmedizin Berlin, Berlin, Germany
⁴ Tokatsu‐Tsujinaka Hospital, Chiba, Japan
⁵ Medical University of Vienna, Wien, Austria
⁶ AbbVie, Inc, North Chicago, United States
⁷ AbbVie Deutschland GmbH Co. KG, Ludwigshafen am Rhein, Germany
⁸ Inflammatory Bowel Disease Center, New York, United States
⁹ CHU Liège and Liège University, Liège, Belgium

Topic
Endoscopy, Histopathology, IBD

Session
IL-23-Blockers in IBD: Part 2

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)